文献库搜索 | GeneLibs

Ansab(M),Ramzan(NUH),Ishaque(G),Araib(E),R... J Gastrointest Cancer 2026-02-12

BRAF V600E-mutated colorectal cancer (CRC) is associated with poor prognosis and resistance to standard chemotherapy. Em...

Zhou(L),Xu(S),Song(Y),Jiang(D),Chen(S) PLoS One None

...BRAF, NRAS, and HRAS were observed both between immune stratification groups (high vs low) and stromal stratification gr...

Donadieu(J),Evseev(D),Pegoraro(F),Sieni(E)... Blood Adv 2026-05-26

...brafenib, 3 of encorafenib, 42 of cobimetinib, 45 of trametinib, and/or 1 prescription of binimetinib; followed 51 times...

Yang(YX),Feng(JW),Ye(J),Wu(WX),Jiang(Y) Ann Ital Chir 2026-02-09

...BRAF V600E mutation was observed in 80.7% (1189/1474) of patients. Stratified analysis by tumor size showed that BRAF V6...

Kato(H) Cancers (Basel) 2026-01-26

...BRAF mutations which may lead to treatment resistance, increased disease burden/progression rate, toxicity tolerance, an...

Chibaudel(B),Carola(E),Mekranter(H),Goyer(... Cancers (Basel) 2026-02-04

...BRAF wild-type tumors (HR 1.81), while no prognostic impact was observed in BRAFV600E mutant tumors (HR 0.90). bTMB was ...

Gutmans(J),Friedlaender(A),Mechahougui(H) Int J Mol Sci 2026-02-06

...BRAF V600E, and rare NTRK or RET fusions, while KRAS mutations are enriched in pancreatobiliary tumors. We recommend ear...

Lin(W),Zhou(X),Wang(Y),Zhou(F) Histopathology 2026-07-00

...BRAF-like' tumours (commonly driven by BRAF^V600E mutations or kinase fusions) and 'RAS-like' tumours (driven by mutatio...

Harvey(A),Walser(E),Lahamm-Andraos(R),Yeo(... Front Endocrinol (Lausanne) None

...BRAF-like" and "RAS-like") more accurately predict iodine avidity, tumor aggressiveness, and treatment response than his...

Wu(N),Wu(Y),Zhang(Q),Naeem(M),Jing(R),Luo(... Front Endocrinol (Lausanne) None

...BRAF mutation. BA treatment upregulates PLAU gene expression, but this increased PLAU protein subsequently interacts wit...